Correlation Between Arcellx and Nuvectis Pharma
Can any of the company-specific risk be diversified away by investing in both Arcellx and Nuvectis Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Arcellx and Nuvectis Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Arcellx and Nuvectis Pharma, you can compare the effects of market volatilities on Arcellx and Nuvectis Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Arcellx with a short position of Nuvectis Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Arcellx and Nuvectis Pharma.
Diversification Opportunities for Arcellx and Nuvectis Pharma
0.37 | Correlation Coefficient |
Weak diversification
The 3 months correlation between Arcellx and Nuvectis is 0.37. Overlapping area represents the amount of risk that can be diversified away by holding Arcellx and Nuvectis Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Nuvectis Pharma and Arcellx is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Arcellx are associated (or correlated) with Nuvectis Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Nuvectis Pharma has no effect on the direction of Arcellx i.e., Arcellx and Nuvectis Pharma go up and down completely randomly.
Pair Corralation between Arcellx and Nuvectis Pharma
Given the investment horizon of 90 days Arcellx is expected to generate 0.35 times more return on investment than Nuvectis Pharma. However, Arcellx is 2.9 times less risky than Nuvectis Pharma. It trades about 0.04 of its potential returns per unit of risk. Nuvectis Pharma is currently generating about -0.08 per unit of risk. If you would invest 8,712 in Arcellx on September 6, 2024 and sell it today you would earn a total of 153.00 from holding Arcellx or generate 1.76% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Very Weak |
Accuracy | 95.45% |
Values | Daily Returns |
Arcellx vs. Nuvectis Pharma
Performance |
Timeline |
Arcellx |
Nuvectis Pharma |
Arcellx and Nuvectis Pharma Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Arcellx and Nuvectis Pharma
The main advantage of trading using opposite Arcellx and Nuvectis Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Arcellx position performs unexpectedly, Nuvectis Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nuvectis Pharma will offset losses from the drop in Nuvectis Pharma's long position.Arcellx vs. Nuvalent | Arcellx vs. Ventyx Biosciences | Arcellx vs. Amylyx Pharmaceuticals | Arcellx vs. Day One Biopharmaceuticals |
Nuvectis Pharma vs. Replimune Group | Nuvectis Pharma vs. Lyra Therapeutics | Nuvectis Pharma vs. Kronos Bio | Nuvectis Pharma vs. Gossamer Bio |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Other Complementary Tools
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
CEOs Directory Screen CEOs from public companies around the world |